Viridian Therapeutics, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsViridian Therapeutics is a commercial-stage biopharmaceutical company that received FDA approval for its first product, Lumvoa (veligrotug), for thyroid eye disease in June 2026 and is building a pipeline in autoimmune and rare diseases.
What they do
Viridian discovers, develops, and commercializes biologics for autoimmune and rare diseases, focusing on thyroid eye disease (TED) and other indications. It has one FDA-approved product, Lumvoa (veligrotug), an IV anti-IGF-1R antibody, and a pipeline including elegrobart (SC anti-IGF-1R), FcRn inhibitors, and a TSHR inhibitor. The company handles discovery, manufacturing, clinical development, and commercialization internally, with commercial infrastructure established for the U.S. launch.
Revenue drivers
- Lumvoa (veligrotug) — FDA-approved in June 2026 for TED; commercial launch began in July 2026 with early patient doses administered. Revenue in Q2 2026 was $284,000, reflecting early launch sales.
- Elegrobart (VRDN-003) — Subcutaneous anti-IGF-1R candidate in phase 3 (REVEAL-1 and REVEAL-2); BLA submission planned for Q1 2027. No revenue yet; future revenue depends on approval and launch.
- Other pipeline programs — FcRn inhibitor (VRDN-008) in phase 1 and TSHR inhibitor in preclinical; no revenue. Future potential from autoimmune indications.
Recent performance
In Q2 2026, Viridian reported revenue of $284,000, up from $141,000 in Q1 2026, reflecting the initial Lumvoa launch. As of June 30, 2026, cash and marketable securities were $982 million, with total assets of $1.10 billion and shareholder equity of $662.1 million. Net loss for 2025 was $342.6 million, and operating cash flow was negative $276.4 million. The company completed a $394 million convertible debt and equity financing in May 2026.
Strategy
Viridian's strategy is to develop differentiated, best-in-class medicines for autoimmune and rare diseases, leveraging validated pathways. For TED, it launched Lumvoa and is advancing elegrobart as a subcutaneous autoinjector for at-home use, aiming for a BLA in Q1 2027. The company is also progressing FcRn and TSHR programs, with an IND for a TSHR antibody planned for Q4 2026. Commercial infrastructure built for Lumvoa is expected to support a potential elegrobart launch with limited incremental investment.
Risks
- Commercial launch execution — Lumvoa is newly launched and must compete with Amgen's Tepezza; early sales are minimal and market adoption is unproven.
- Regulatory approval dependence — Elegrobart and other pipeline candidates require FDA and EMA approvals; delays or failures could derail growth.
- Financial losses and capital needs — The company has persistent net losses and negative operating cash flow, and may need additional financing despite recent $394 million raise.
- Clinical trial and manufacturing risks — Phase 1 data for VRDN-008 and IND for TSHR program are pending; manufacturing or supply chain issues could delay development.
Outlook
Management expects Lumvoa launch momentum to build, with early engagement with 95% of 2,000 core prescribers. Elegrobart BLA submission is on track for Q1 2027, and VRDN-008 phase 1 data are expected in 2H 2026. An IND for the TSHR inhibitor is planned for Q4 2026. The company believes its current cash position will fund operations through these milestones.